BAYER HELLAS AG
Bayer is an innovation company with more than 150-year history and core competencies in the fields of health care and agriculture. The company develops new molecules for use in innovative products and solutions to improve the health of humans, animals and plants. Bayer’s research and development activities are based on a profound understanding of the biochemical processes in living organisms.
An analysis by a well-known branding agency Interbrand in 2015 valued the Bayer brand at €6.3 billion.
Bayer’s goal is to achieve and sustain leadership positions in the market, thus creating value for customers, stockholders and employees. To this end, corporate strategy is designed to help solve some of the most pressing challenges facing mankind, and by doing this exceptionally well, strengthen the company’s earning power.
The Pharmaceuticals Division focuses on prescription products, especially for cardiology and women’s healthcare, and on specialty therapeutics in the areas of oncology, hematology and ophthalmology. The division also comprises the Radiology Business Unit which markets contrast-enhanced diagnostic imaging equipment together with the necessary contrast agents.
The Consumer Health Division markets mainly non-prescription products in the dermatology, dietary supplement, analgesic, gastrointestinal, allergy, cold and flu, foot care, sun protection and cardiovascular risk prevention categories. These products include globally known brands such as Bepanthol, Rennie, Aspirin and Aspro Clear.
Astellas Pharma Inc., based in Tokyo, Japan, was established in Apr. 1, 2005, after the merger of the mother companies Yamanouchi (founded in 1923 in Osaka, Japan) and Fujisawa (founded in 1894 in Osaka, Japan).
In Europe, Astellas Pharma Europe Ltd. operates in 37 countries, speaking 23 main languages and has 3.500 employees. The headquarters are based in the UK, and support the affiliate teams across Europe, Australia and Canada, working in collaboration with the Manufacturing and Medical & Development sites in Ireland and the Netherlands.
Astellas is a company dedicated to improving the health of people around the world through the provision of innovative and reliable pharmaceutical products. We are working at the forefront of healthcare change and the values of patient focus, ownership, results, openness and integrity are the foundation of our culture.
At Astellas we are committed to turning innovative science into value for patients. Changing tomorrow is the ethos that guides everything we do.
Across our areas of therapeutic expertise, we use our agility to match scientific breakthroughs to the unmet medical needs of people around the world, and the many healthcare professionals and caregivers who support them.
Astellas invests in new medicines, technologies and therapeutic areas to stay at the cutting-edge of science and builds partnerships and networks with others who share our vision to improve the future of medicine. Our ‘Focus Area’ approach to discovery combines biology, modality/technology and disease, to generate high-quality programs that seek to drive innovation.
We invest in our people whose passion inspires us to be a dynamic organization, committed to continually learning and challenging ourselves to make a difference to the lives of patients.
For more information, please visit our website at https://www.astellas.com
Established in 2016 through the acquisition of Bayer Diabetes Care by Panasonic Healthcare Holdings, Ascensia Diabetes Care is a global company dedicated to improving the health and lives of people with diabetes. Already including the world-renowned CONTOUR™ range of blood glucose monitoring systems, we are committed to adding more innovative and life-changing products to our portfolio.